News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Novartis' canakinumab cuts risk for heart attack survivors Novartis to discuss canakinumab results with regulators.
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
Views & Analysis Verily, Novartis join fund to support Europe’s biotech entre... New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
